Cargando…
Association of HLA diversity with the risk of 25 cancers in the UK Biobank
BACKGROUND: The human leukocyte antigen (HLA) is a highly polymorphic region, and HLA diversity may play a role in presenting tumour-associated peptides and inducing immune responses. However, the effect of HLA diversity on cancers has not been fully assessed. We aimed to explore the role of HLA div...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10189092/ https://www.ncbi.nlm.nih.gov/pubmed/37148584 http://dx.doi.org/10.1016/j.ebiom.2023.104588 |
_version_ | 1785043009841135616 |
---|---|
author | Wang, Qiao-Ling Wang, Tong-Min Deng, Chang-Mi Zhang, Wen-Li He, Yong-Qiao Xue, Wen-Qiong Liao, Ying Yang, Da-Wei Zheng, Mei-Qi Jia, Wei-Hua |
author_facet | Wang, Qiao-Ling Wang, Tong-Min Deng, Chang-Mi Zhang, Wen-Li He, Yong-Qiao Xue, Wen-Qiong Liao, Ying Yang, Da-Wei Zheng, Mei-Qi Jia, Wei-Hua |
author_sort | Wang, Qiao-Ling |
collection | PubMed |
description | BACKGROUND: The human leukocyte antigen (HLA) is a highly polymorphic region, and HLA diversity may play a role in presenting tumour-associated peptides and inducing immune responses. However, the effect of HLA diversity on cancers has not been fully assessed. We aimed to explore the role of HLA diversity on cancer development. METHODS: A pan-cancer analysis was performed to evaluate the effect of HLA diversity, measured by HLA heterozygosity and HLA evolutionary divergence (HED), on the susceptibility of 25 cancers in the UK Biobank. FINDINGS: We observed that the diversity of HLA class II locus was associated with a lower risk of lung cancer (OR(hetero) = 0.94, 95% CI = 0.90–0.97, P = 1.29 × 10(−4)) and head and neck cancer (OR(hetero) = 0.91, 95% CI = 0.86–0.96, P = 1.56 × 10(−3)). Besides, a lower risk of non-Hodgkin lymphoma was associated with an increased diversity of HLA class I (OR(hetero) = 0.92, 95% CI = 0.87–0.98, P = 8.38 × 10(−3)) and class II locus (OR(hetero) = 0.89, 95% CI = 0.86–0.92, P = 1.65 × 10(−10)). A lower risk of Hodgkin lymphoma was associated with the HLA class I diversity (OR(hetero) = 0.85, 95% CI = 0.75–0.96, P = 0.011). The protective effect of HLA diversity was mainly observed in pathological subtypes with higher tumour mutation burden, such as lung squamous cell carcinoma (P = 9.39 × 10(−3)) and diffuse large B cell lymphoma (P(class I) = 4.12 × 10(−4); P(class Ⅱ) = 4.71 × 10(−5)), as well as the smoking subgroups of lung cancer (P = 7.45 × 10(−5)) and head and neck cancer (P = 4.55 × 10(−3)). INTERPRETATION: We provided a systematic insight into the effect of HLA diversity on cancers, which might help to understand the etiological role of HLA on cancer development. FUNDING: This study was supported by grants from the 10.13039/501100001809National Natural Science Foundation of China (82273705, 82003520); the 10.13039/501100021171Basic and Applied Basic Research Foundation of Guangdong Province, China (2021B1515420007); the Science and Technology Planning Project of Guangzhou, China (201804020094); Sino-Sweden Joint Research Programme (81861138006); the 10.13039/501100001809National Natural Science Foundation of China (81973131, 81903395, 81803319, 81802708). |
format | Online Article Text |
id | pubmed-10189092 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-101890922023-05-18 Association of HLA diversity with the risk of 25 cancers in the UK Biobank Wang, Qiao-Ling Wang, Tong-Min Deng, Chang-Mi Zhang, Wen-Li He, Yong-Qiao Xue, Wen-Qiong Liao, Ying Yang, Da-Wei Zheng, Mei-Qi Jia, Wei-Hua eBioMedicine Articles BACKGROUND: The human leukocyte antigen (HLA) is a highly polymorphic region, and HLA diversity may play a role in presenting tumour-associated peptides and inducing immune responses. However, the effect of HLA diversity on cancers has not been fully assessed. We aimed to explore the role of HLA diversity on cancer development. METHODS: A pan-cancer analysis was performed to evaluate the effect of HLA diversity, measured by HLA heterozygosity and HLA evolutionary divergence (HED), on the susceptibility of 25 cancers in the UK Biobank. FINDINGS: We observed that the diversity of HLA class II locus was associated with a lower risk of lung cancer (OR(hetero) = 0.94, 95% CI = 0.90–0.97, P = 1.29 × 10(−4)) and head and neck cancer (OR(hetero) = 0.91, 95% CI = 0.86–0.96, P = 1.56 × 10(−3)). Besides, a lower risk of non-Hodgkin lymphoma was associated with an increased diversity of HLA class I (OR(hetero) = 0.92, 95% CI = 0.87–0.98, P = 8.38 × 10(−3)) and class II locus (OR(hetero) = 0.89, 95% CI = 0.86–0.92, P = 1.65 × 10(−10)). A lower risk of Hodgkin lymphoma was associated with the HLA class I diversity (OR(hetero) = 0.85, 95% CI = 0.75–0.96, P = 0.011). The protective effect of HLA diversity was mainly observed in pathological subtypes with higher tumour mutation burden, such as lung squamous cell carcinoma (P = 9.39 × 10(−3)) and diffuse large B cell lymphoma (P(class I) = 4.12 × 10(−4); P(class Ⅱ) = 4.71 × 10(−5)), as well as the smoking subgroups of lung cancer (P = 7.45 × 10(−5)) and head and neck cancer (P = 4.55 × 10(−3)). INTERPRETATION: We provided a systematic insight into the effect of HLA diversity on cancers, which might help to understand the etiological role of HLA on cancer development. FUNDING: This study was supported by grants from the 10.13039/501100001809National Natural Science Foundation of China (82273705, 82003520); the 10.13039/501100021171Basic and Applied Basic Research Foundation of Guangdong Province, China (2021B1515420007); the Science and Technology Planning Project of Guangzhou, China (201804020094); Sino-Sweden Joint Research Programme (81861138006); the 10.13039/501100001809National Natural Science Foundation of China (81973131, 81903395, 81803319, 81802708). Elsevier 2023-05-04 /pmc/articles/PMC10189092/ /pubmed/37148584 http://dx.doi.org/10.1016/j.ebiom.2023.104588 Text en © 2023 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Articles Wang, Qiao-Ling Wang, Tong-Min Deng, Chang-Mi Zhang, Wen-Li He, Yong-Qiao Xue, Wen-Qiong Liao, Ying Yang, Da-Wei Zheng, Mei-Qi Jia, Wei-Hua Association of HLA diversity with the risk of 25 cancers in the UK Biobank |
title | Association of HLA diversity with the risk of 25 cancers in the UK Biobank |
title_full | Association of HLA diversity with the risk of 25 cancers in the UK Biobank |
title_fullStr | Association of HLA diversity with the risk of 25 cancers in the UK Biobank |
title_full_unstemmed | Association of HLA diversity with the risk of 25 cancers in the UK Biobank |
title_short | Association of HLA diversity with the risk of 25 cancers in the UK Biobank |
title_sort | association of hla diversity with the risk of 25 cancers in the uk biobank |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10189092/ https://www.ncbi.nlm.nih.gov/pubmed/37148584 http://dx.doi.org/10.1016/j.ebiom.2023.104588 |
work_keys_str_mv | AT wangqiaoling associationofhladiversitywiththeriskof25cancersintheukbiobank AT wangtongmin associationofhladiversitywiththeriskof25cancersintheukbiobank AT dengchangmi associationofhladiversitywiththeriskof25cancersintheukbiobank AT zhangwenli associationofhladiversitywiththeriskof25cancersintheukbiobank AT heyongqiao associationofhladiversitywiththeriskof25cancersintheukbiobank AT xuewenqiong associationofhladiversitywiththeriskof25cancersintheukbiobank AT liaoying associationofhladiversitywiththeriskof25cancersintheukbiobank AT yangdawei associationofhladiversitywiththeriskof25cancersintheukbiobank AT zhengmeiqi associationofhladiversitywiththeriskof25cancersintheukbiobank AT jiaweihua associationofhladiversitywiththeriskof25cancersintheukbiobank |